IL17A and atherosclerosis: Assuming that the severity of atherosclerosis symptoms is associated with the degree of inflammation (active expression of IL-17A), a decreasing percentage of methylation was expected in control subjects, whereas pCAD patients would have the lowest level of methylation, as reported for IL-6 in CAD [33,34].